Elamipretide for Dry AMD: What the Research Shows So Far

Elamipretide is an investigational, mitochondria-targeted peptide that has been studied as a possible treatment for dry age-related macular degeneration (dry AMD), including the advanced stage known as geographic atrophy. The FDA has not approved elamipretide for dry AMD or any other condition, and the largest randomized trial in this disease did not meet its primary endpoint. Outside of clinical research, the drug is not legally available to patients in the United States.

What Is Elamipretide?

For anyone asking what is elamipretide, the short answer is that it is a synthetic tetrapeptide developed by Stealth BioTherapeutics and also known as SS-31, MTP-131, and the proposed brand name Forzinity. It was designed to concentrate inside cells at the mitochondria, the organelles that generate most of a cell's energy.

The elamipretide structure is unusual for a peptide. It contains four amino acids — D-arginine, dimethyltyrosine, lysine, and phenylalanine — capped with an amide group. The positively charged arginine and the aromatic dimethyltyrosine give the molecule both water solubility and the ability to cross cell membranes.

The elamipretide mechanism of action centers on cardiolipin, a phospholipid found almost exclusively on the inner mitochondrial membrane. Elamipretide binds cardiolipin and appears to stabilize the membrane's folded cristae structure, which helps the electron transport chain work more efficiently. Laboratory studies show increased ATP production and reduced leakage of reactive oxygen species.

Why Mitochondria Matter in Dry AMD

The retina is one of the most energy-demanding tissues in the human body. Retinal pigment epithelium (RPE) cells and photoreceptors are densely packed with mitochondria, and they operate under constant oxidative stress from light exposure and oxygen metabolism.

In dry AMD, drusen accumulate beneath the retina, RPE cells become dysfunctional, and photoreceptors gradually die. Geographic atrophy is the advanced form of dry AMD, in which patches of RPE and photoreceptor loss create permanent blind spots in central vision.

Researchers have found evidence of impaired mitochondrial function in AMD eyes, which is the rationale for testing a mitochondria-targeted drug. If declining energy production contributes to RPE and photoreceptor loss, then supporting mitochondrial health could potentially slow the disease.

What the Dry AMD Trials Found

Two human studies have evaluated elamipretide specifically in dry AMD.

• ReCLAIM (Phase 1, open-label): 40 participants with dry AMD received 40 mg subcutaneously once daily for 24 weeks. The study reported improvements in low-luminance visual acuity and in some retinal imaging measures, including preservation of the ellipsoid zone.
• ReCLAIM-2 (Phase 2, randomized, double-masked): approximately 176 participants were assigned to elamipretide or placebo for 48 weeks. The trial did not meet its primary endpoint of change in low-luminance visual acuity. Secondary and exploratory analyses suggested slower geographic atrophy progression in the central subfield and better ellipsoid zone preservation in certain participants.

Trial	Design	Participants	Dose	Primary Outcome
ReCLAIM	Phase 1, open-label	40	40 mg daily, 24 weeks	Signals of visual and structural improvement, with no control group
ReCLAIM-2	Phase 2, randomized, placebo-controlled	About 176	40 mg daily, 48 weeks	Did not meet the primary endpoint; positive signals in secondary analyses

These results should be read carefully. Open-label findings can reflect placebo effects and natural variability, and secondary endpoint signals in a trial that missed its primary endpoint are considered hypothesis-generating rather than proven benefit.

Elamipretide has not been shown in a randomized controlled trial to reverse or stop vision loss from dry AMD.

How Elamipretide Is Given

Elamipretide is not a pill and not an eye drop. In dry AMD research it is delivered as a subcutaneous elamipretide injection into the fatty tissue of the abdomen, thigh, or upper arm, usually once a day. Trial participants are trained to self-inject at home with a small needle.

Daily dosing is necessary because the peptide is cleared from the bloodstream relatively quickly. Because the drug reaches the eye through the bloodstream rather than through direct delivery, researchers have debated whether enough of it reaches the retina to produce a meaningful effect.

FDA Status, Availability, and Cost

There is currently no elamipretide fda approval for dry AMD, geographic atrophy, or any other indication in the United States. Stealth BioTherapeutics has sought approval for Barth syndrome, a rare mitochondrial disease, but that application received a Complete Response Letter from the FDA, and a later FDA advisory committee vote did not support the evidence of efficacy.

Because the drug is not marketed, there is no published elamipretide cost and no insurance coverage pathway. Participants in clinical trials do not pay for the study drug.

Peptides sold online as research chemicals are not FDA-approved, are not manufactured under pharmaceutical sterility and purity standards, and should not be treated as an equivalent product. Injecting an unverified peptide carries real risks of contamination, dosing errors, and infection.

Safety, Side Effects, and What Patients Should Know

Elamipretide has generally been well tolerated in clinical studies. The most frequently reported issues are injection site reactions such as redness, pain, or swelling. Less common complaints include itching, hives, nausea, and headache.

Serious side effects have been uncommon, but the total number of people exposed to the drug remains small, and long-term safety data are limited. Anyone with dry AMD should discuss experimental options with a retina specialist rather than seeking the drug independently.

Approved Treatments for Advanced Dry AMD

Two complement inhibitors are FDA-approved for geographic atrophy and are given by intravitreal injection in a clinic. Nutritional supplementation with the AREDS2 formula is commonly recommended for intermediate dry AMD, and anti-VEGF injections treat the wet form of the disease.

Treatment	How It Is Given	Regulatory Status
Elamipretide	Subcutaneous injection, once daily	Investigational; not FDA-approved for any indication
Pegcetacoplan (Syfovre)	Intravitreal injection every 25 to 60 days	FDA-approved for geographic atrophy
Avacincaptad pegol (Izervay)	Intravitreal injection, typically monthly	FDA-approved for geographic atrophy
AREDS2 formula vitamins	Oral supplement, daily	Not a drug; widely used for intermediate dry AMD

Each of these options carries different risks, benefits, and eligibility criteria. A retina specialist can explain which, if any, fits a specific stage of disease and a specific patient.

COMMON QUESTIONS

Frequently Asked Questions

Is elamipretide FDA-approved for dry AMD?

No. The FDA has not approved elamipretide for dry AMD, geographic atrophy, or any other condition. The manufacturer has pursued approval in Barth syndrome, but that application received a Complete Response Letter, and an FDA advisory committee vote did not support the evidence of efficacy. Elamipretide remains an investigational drug available only through clinical trials.

Does elamipretide actually work for dry AMD?

The Phase 2 ReCLAIM-2 trial did not meet its primary endpoint, which was a change in low-luminance visual acuity compared with placebo. Secondary analyses suggested slower geographic atrophy progression in some subgroups, but that is not proof of a reliable vision benefit. A larger confirmatory trial would be needed before any conclusions could be drawn.

Can I get elamipretide outside of a clinical trial?

No. Elamipretide is not sold by prescription or as a legal over-the-counter product in the United States. Peptides marketed online as research chemicals are not FDA-regulated and may be impure or unsafe to inject. Patients interested in elamipretide should ask a retina specialist about clinical trial eligibility.